Syncona Ltd has founded Quell Therapeutics, a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed £34.0 million with a further £1.0 million being contributed by UCL Technology Fund. Syncona will have a 69.3 per cent stake (1) in the business, with the first tranche of the Series A commitment of £8.3m paid in May 2019.